Affordable Access

The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

Authors
  • Gagneux, Sebastien
  • Long, Clara Davis
  • Small, Peter M
  • Van, Tran
  • Schoolnik, Gary K
  • Bohannan, Brendan J M
Type
Published Article
Journal
Science
Publisher
American Association for the Advancement of Science (AAAS)
Publication Date
Jun 30, 2006
Volume
312
Issue
5782
Pages
1944–1946
Identifiers
PMID: 16809538
Source
Medline
License
Unknown

Abstract

Mathematical models predict that the future of the multidrug-resistant tuberculosis epidemic will depend on the fitness cost of drug resistance. We show that in laboratory-derived mutants of Mycobacterium tuberculosis, rifampin resistance is universally associated with a competitive fitness cost and that this cost is determined by the specific resistance mutation and strain genetic background. In contrast, we demonstrate that prolonged patient treatment can result in multidrug-resistant strains with no fitness defect and that strains with low- or no-cost resistance mutations are also the most frequent among clinical isolates.

Report this publication

Statistics

Seen <100 times